Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Next Generation Analytics, Palo Alto, California.
Cancer Res. 2020 Feb 1;80(3):458-470. doi: 10.1158/0008-5472.CAN-18-2932. Epub 2019 Nov 29.
Standard chemotherapy for acute myeloid leukemia (AML) targets proliferative cells and efficiently induces complete remission; however, many patients relapse and die of their disease. Relapse is caused by leukemia stem cells (LSC), the cells with self-renewal capacity. Self-renewal and proliferation are separate functions in normal hematopoietic stem cells (HSC) in steady-state conditions. If these functions are also separate functions in LSCs, then antiproliferative therapies may fail to target self-renewal, allowing for relapse. We investigated whether proliferation and self-renewal are separate functions in LSCs as they often are in HSCs. Distinct transcriptional profiles within LSCs of / murine AML were identified using single-cell RNA sequencing. Single-cell qPCR revealed that these genes were also differentially expressed in primary human LSCs and normal human HSPCs. A smaller subset of these genes was upregulated in LSCs relative to HSPCs; this subset of genes constitutes "LSC-specific" genes in human AML. To assess the differences between these profiles, we identified cell surface markers, CD69 and CD36, whose genes were differentially expressed between these profiles. mouse reconstitution assays resealed that only CD69 LSCs were capable of self-renewal and were poorly proliferative. In contrast, CD36 LSCs were unable to transplant leukemia but were highly proliferative. These data demonstrate that the transcriptional foundations of self-renewal and proliferation are distinct in LSCs as they often are in normal stem cells and suggest that therapeutic strategies that target self-renewal, in addition to proliferation, are critical to prevent relapse and improve survival in AML. SIGNIFICANCE: These findings define and functionally validate a self-renewal gene profile of leukemia stem cells at the single-cell level and demonstrate that self-renewal and proliferation are distinct in AML. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/3/458/F1.large.jpg.
急性髓系白血病(AML)的标准化疗针对增殖细胞,能有效诱导完全缓解;然而,许多患者复发并死于疾病。复发是由白血病干细胞(LSC)引起的,LSC 具有自我更新能力。在稳态条件下,自我更新和增殖是正常造血干细胞(HSC)的两个独立功能。如果 LSCs 中也存在这两种功能,那么抗增殖疗法可能无法靶向自我更新,从而导致复发。我们研究了 LSCs 中的增殖和自我更新是否像在 HSCs 中那样是两个独立的功能。通过单细胞 RNA 测序鉴定了 / 鼠 AML 中 LSCs 内的独特转录谱。单细胞 qPCR 显示,这些基因在原发性人 LSCs 和正常人类 HSPCs 中也有差异表达。这些基因的一个较小亚组在 LSCs 中相对 HSPCs 上调;该亚组基因构成人 AML 中的“LSC 特异性”基因。为了评估这些谱之间的差异,我们鉴定了细胞表面标志物 CD69 和 CD36,它们的基因在这些谱之间表达不同。 鼠重建实验表明,只有 CD69 LSCs 具有自我更新能力且增殖能力差。相比之下,CD36 LSCs 无法移植白血病,但增殖能力很强。这些数据表明,LSCs 中的自我更新和增殖的转录基础与正常干细胞中通常存在的转录基础不同,并表明除了增殖之外,靶向自我更新的治疗策略对于防止复发和改善 AML 患者的生存至关重要。 意义:这些发现定义并在单细胞水平上功能验证了白血病干细胞的自我更新基因谱,并证明了 AML 中自我更新和增殖是不同的。